文献速递青光眼眼底病与葡萄膜炎

通过过表达转录因子MAX的神经保护性基因治疗在大鼠青光眼性神经变性模型中的作用

Neuroprotective Gene Therapy by Overexpression of the Transcription Factor MAX in Rat Models of Glaucomatous Neurodegeneration.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2022-01-01

本研究基于既往发现转录因子Myc相关蛋白X(MAX)核内容物减少是视网膜神经节细胞(RGC)变性的早期事件,旨在检验过表达人MAX是否对RGC损伤具有神经保护作用。研究采用三种RGC变性大鼠模型:离体视网膜外植体培养、视神经挤压模型和高眼压青光眼模型,通过玻璃体内注射重组腺相关病毒(rAAV)过表达MAX或绿色荧光蛋白(GFP)。结果显示,在全部三种RGC损伤模型中,过表达MAX的基因治疗均防止了RGC死亡,并在高眼压模型中防止了视神经变性和电生理缺陷。

要点

  • 在离体视网膜外植体、视神经挤压和高眼压三种大鼠模型中,过表达MAX的rAAV基因治疗均防止了RGC死亡。
  • 在高眼压青光眼模型中,过表达MAX还防止了视神经变性和电生理缺陷。
  • 研究为基于过表达MAX的青光眼性神经变性新型神经保护基因治疗提供了概念验证。

核心结论

  • 实验为基于过表达MAX的青光眼性神经变性新型神经保护基因治疗提供了概念验证。

研究设计与样本

  • 研究使用Lister Hooded大鼠,通过玻璃体内注射rAAV2-MAX或对照载体rAAV2-GFP实现视网膜内MAX或GFP过表达。
  • 采用三种RGC变性模型:(1)离体视网膜外植体培养30小时,取自出生时接受玻璃体内注射rAAV2-MAX或rAAV2-GFP的14日龄大鼠眼;(2)视神经挤压模型,1月龄大鼠接受玻璃体内注射rAAV2-MAX或rAAV2-GFP,4周后进行手术;(3)高眼压青光眼模型,1月龄大鼠接受玻璃体内注射rAAV2-MAX或rAAV2-GFP,4周后进行角膜缘血管丛烧灼。

主要发现

  • 在全部三种RGC损伤模型中,过表达MAX的基因治疗均防止了RGC死亡。
  • 在高眼压模型中,过表达MAX还防止了视神经变性和电生理缺陷。
  • 细胞死亡通过检测固缩核和TUNEL技术评估,并与离体视网膜外植体模型中的MAX免疫含量相关。
  • MAX表达通过定量RT-PCR检测;在高眼压模型中,体内损伤后14天通过DiI逆行标记或BRN3a免疫染色定量RGC存活。
  • RGC功能完整性通过图形视网膜电图分析,视神经损伤在半薄切片中检查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Based on our preview evidence that reduced nuclear content of the transcription factor Myc-associated protein X (MAX) is an early event associated with degeneration of retinal ganglion cells (RGCs), in the present study, our purpose was to test whether the overexpression of human MAX had a neuroprotective effect against RGC injury. METHODS: Overexpression of either MAX or green fluorescent protein (GFP) in the retina was achieved by intravitreal injections of recombinant adenovirus-associated viruses (rAAVs). Lister Hooded rats were used in three models of RGC degeneration: (1) cultures of retinal explants for 30 hours ex vivo from the eyes of 14-day-old rats that had received intravitreal injections of rAAV2-MAX or the control vector rAAV2-GFP at birth; (2) an optic nerve crush model, in which 1-month-old rats received intravitreal injection of either rAAV2-MAX or rAAV2-GFP and, 4 weeks later, were operated on; and (3) an ocular hypertension (OHT) glaucoma model, in which 1-month-old rats received intravitreal injection of either rAAV2-MAX or rAAV2-GFP and, 4 weeks later, were subject to cauterization of the limbal plexus. Cell death was estimated by detection of pyknotic nuclei and TUNEL technique and correlated with MAX immunocontent in an ex vivo model of retinal explants. MAX expression was detected by quantitative RT-PCR. In the OHT model, survival of RGCs was quantified by retrograde labeling with DiI or immunostaining for BRN3a at 14 days after in vivo injury. Functional integrity of RGCs was analyzed through pattern electroretinography, and damage to the optic nerve was examined in semithin sections. RESULTS: In all three models of RGC insult, gene therapy by overexpression of MAX prevented RGC death. Also, ON degeneration and electrophysiologic deficits were prevented in the OHT model. CONCLUSIONS: Our experiments offer proof of concept for a novel neuroprotective gene therapy for glaucomatous neurodegeneration based on overexpression of MAX.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Lani-Louzada R, Marra C, Dias MS, et al. Neuroprotective Gene Therapy by Overexpression of the Transcription Factor MAX in Rat Models of Glaucomatous Neurodegeneration. Invest Ophthalmol Vis Sci. 2022. PMID: 35103748. doi:10.1167/iovs.63.2.5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。